Biological basis of tobacco addiction: Implications for smoking-cessation treatment

Indian Journal of Psychiatry

Volumn 52, Issue 4, 2010, Pages 301-307

  Jiloha, R C ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

Acetylcholine receptors; addiction; dopamine; nicotine

Indexed keywords

ACETYLCHOLINE; AMFEBUTAMONE; CHOLINERGIC RECEPTOR; CLONIDINE; DOPAMINE; NICOTINE; NICOTINE PATCH; NICOTINE VACCINE; NICOTINIC RECEPTOR; NORTRIPTYLINE; VARENICLINE;

ACETYLCHOLINE RELEASE; BEHAVIOR; HUMAN; LEARNING; MEMORY; NEUROBIOLOGY; NEUROTRANSMITTER RELEASE; NICOTINE REPLACEMENT THERAPY; NONHUMAN; REINFORCEMENT; REVIEW; REWARD; SMOKING CESSATION PROGRAM; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

EID: 78650955400     PISSN: 00195545     EISSN: 19983794     Source Type: Journal    
DOI: 10.4103/0019-5545.74303     Document Type: Review

References (71)

1. Ashton H, Stepney R. Smoking: Psychology and Pharmacology. London: Travistock Publications; 1982.
2. Jiloha RC. Tobacco Use: Health and Behaviour. Delhi: New Age Publication; 2008.
3. Johannes W. Tobacco and Shamanism. Yale: Yale University Press; 1987.
4. Benowitz NL. Neurobiology of nicotine addiction: Implications for smoking cessation. Am J Med 2008;121:S3-10.
5. Volkow ND. Tobacco Addiction: Research Report Series. National Institute of Drug abuse (NIDA); 2010.
6. Chojar AK. Tobacco Cultivation and Marketing. New Delhi: Deep and Deep Publications Private Limited; 2002.
7. Jain R, Mukherjee K. Biological basis of nicotine addiction. Indian J Pharmacol 2003;35:281-9.
8. Larson PS, Haag HB, Silvette. Tobacco: Experimental and clinical studies. Baltimore: Williams and Wilkins; 1961.
9. Benowitz NL, Porchet H, Sheiner L. Nicotine absorption and cardiovascular effects with smokeless tobacco use: Comparison with cigarette and nicotine gum. Clin Pharmacol Ther 1988;44:23-8.
10. Benowitz NL, Jacob P 3rd. Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther 1984;35:499-504.
11. Collins AC, Luo Y, Selvaag S, Marks MJ. Sensitivity to nicotine and brain nicotinic receptor are altered by chronic nicotine and mecamylamine infusion. J Pharmacol Exp Ther 1994;271:125-33.
12. Picciotto MR, Caldarone BJ, King SL, Zacharion V. Nicotine receptors in the brain: Links between molecular biology and behaviour. Neuropsychopharmacology 2000;22:451-6.
13. Clarke PB, Pert A. Autoradiographic evidences for nicotine receptors in nigrostriatal and mesolimbic dopaminergic neurons. Brain Res 1985;348:355-8.
14. Epping-Jordan MP, Watkin SS, Koob GF, Markou A. A dramatic decrease in brain reward function during nicotine withdrawal. Nature 1998;393:76-9.
15. Picciotto MR. Common aspects of the action of nicotine and other drugs of abuse. Drug Alcohol Depend 1998;51:165-72.
16. Pidoplichko VI, Debiasi M, Williams JT, Dani JA. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 1997;390:401-4.
17. George TP, Vernico CD, Picciotto MR, Roth RH. Nicotine modulation of mesofrontal dopamine neurons: Pharmacologic and neuroanatomic characterization. J Pharmacol Exp Ther 2000;295:58-66.
18. McGhee DS, Heath MJ, Gelber S, Devay R. Nicotinic enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science 1995;269:1692-6.
19. Wonnacott S, Drasdo A, Sandeerson R, Rowell P. Presynaptic nicotine receptors and modulation of transmission release. In: Block G, Marsh J, editors. The Biology of Nicotine Dependence. Chichester: Wiley; 1990.
20. Costall B, Kelly ME, Nylor NJ, Onaivi ES. The action of nicotine and cocaine in a mouse model of anxiety. Pharmacol Biochem Behav 1989;33:197-203.
21. Dani JA, De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 2001;70:439-46.
22. Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM. Acetylcholine receptors containing the beta 2 subunit are involved in the reinforcing properties of nicotine. Nature 1998;391:173-7.
23. Mascos U, Molles BE, Pons S. Nicotine reinforcement and cognition restored by targeted expression of nicotine receptors. Naure 2005;436:103-7.
24. Aberger K, Chitravanshi VC, Sapru HN. Cardiovascular response to microinjections of nicotine into the caudal ventrolateral medulla of the rat. Brain Res 2001;892:138-46.
25. Levin ED, Bettegowda C, Blosser J, Gordon J. AR-R177779, and alfa7 nicotine agonist improves learning and memory in rats. Behav Pharmacol 1999;10:675-80.
26. Hajos M, Hurst RS, Hoffmann WE. The selective alfa7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3yl]- chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anaesthetized rats. J Pharmacol Exp Ther 2005;312:1213-22.
27. Dwoskin LP, Teng L, Buxton ST, Crooks PA. (S)-(-)-Cotinine the major nicotine metabolite of nicotine, stimulates nicotine receptors to evoke[3H] dopamine release from rat striatal slices in a calcium dependent manner. J Pharmacol Exp Ther 1999;288:905-11.
28. Wang H, Sun X. Desensitized nicotine receptors in brain. Brain Res Rev 2005;48:420-37.
29. Dani JA, Heinemann S. Moleculat and cellular aspects of nicotine abuse. Neuron 1996;16:905-8.
30. Lu Y, Grady S, Marks MJ, Picciotto M, Chaneux JP, Collins AC. Pharmacological characteristiucs of nicotine receptor-stimulated GABA release from mouse brain synaptosomes. J Pharmacol Exp Ther 1998;67:331-7.
31. Zhu PJ, Chiappinelli VA. Nicotine modulates evoked GABArgec transmission in the brain. J Neurophysiol 1999;82:3041-5.
32. Yin R, French ED. A comparison of effects of nicotine on dopamine and norepinephrine neurons in the rat ventral tegmental area: In vitro electrophysiological study. Brain Res Bull 2000;51:507-14.
33. Fu Y, Matta SG, Valentine JD, Sharp BM. Desensitization and resensitization of epinephrine release in the rat hippocampus with repeated nicotine administration. Neurosci 1998;241:147-50.
34. Gilbert DG. Smoking: Individual differences, psychopathology, and emotion. Washington DC: Taylor and Francis; 1995.
35. Graham S, Crouch S, Levin ML, Bock FG. Variations in amounts of tobacco tar reprieved from selected models of smoking behaviour simulated by smoking machine. Cancer Res 1963;23:1025-30.
36. Griffths RR, Henningfield JE. Experimental analysis of human cigarette smoking. Behav Fed Proc 1982;40:234-40.
37. Gritz ER, Rose JE, Jarvik ME. Regulation of tobacco smoke intake with paced cigarette presentation. Pharmacol Biochem Behav 1983;18:457-62.
38. Cao W, Burkholder T, Wilkins I, Collins AC. A genetic comparison of behavioural actions of ethanol and nicotine in the mirrored chamber. Pharmacol Biochem Behav 1993;54:803-9.
39. Brioni JD, O'Neill A, Kim DJ, Decker MW. Nicotine receptor agonists exhibit anxiolytic like effects on the elevated plus maze test. Eur J Pharmacol 1993;238:1-8.
40. Volikow ND, Fowler JS, Ding YS, Wang GJ, Gatley SJ. Imaging the neurochemistry of nicotine actions: Studies with positron emission tomography. Nicotine Tob Res 1999;1:127-32 and 139-40.
41. Brody AL. Functional brain imaging of tobacco use and dependence. J Psychiatr Res 2006;40:404-18.
42. Imperato A, Mulas A, Di Chiara G. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 1996;132:137-8.
43. Nestler E. Molecular mechanism of drug addiction. J Eurosci 1992;12:2439-50.
44. Benwell ME, Balfrm DJ, Khadra LF. Studies on the influence of nicotine infusions on mesolimbic dopamine and locomotor responses to nicotine. Clin Investig 1994;72:233-9.
45. Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996;382:255-7.
46. Corigall WA, Franklin KB, Coen KM, Clarke PB. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 1992;107:285-9.
47. Leikola-Pelho T, Jackson DM. Preferential stimulation of locomotor activity by ventral tegmentum microinjections of (-) nicotine. Pharmacol Toxicol 1992;70:50-2.
48. Museo E, Wise RA. Place preference conditioning with ventral tegmental injections of cytisine. Life Sci 1994;55:1179-86.
49. Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci 2005;8:1445-9.
50. Wonnacott S. Presynaptic nicotine Ach receptors. Trends Neurosci 1997;20:92-8.
51. Tyndale RF, Pianezza ML, Sellers EM. A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption. Nicotine Tob Res 1999;1:S63-7.
52. Vandenbergh DJ, Bennett CJ, Grant D, Strasser AA, O'Connor R, Stauffer RL. Smoking status and human dopamine transporter variable number of tandem reports (VNTR) polymorphism: Failure to replicate and finding that never smokers may be different. Nicotine Tob Res 2000;4:333-40.
53. Hall W, Madden P, Lynskey M. The genetics of tobacco use: Findings and policy implications. Tob Control 2002;11:119-24.
54. Clarke PB, Fibiger HC. Apparent absence of nicotine-induced conditioned place preference in rats. Psychopharmacology 1987;92:84-8.
55. Rose JE, Behm FM, Ramsey C, Ritchie JC Jr. Pkatelet monoamine oxidase, smoking cessation and tobacco withdrawal symptoms. Nicotine Tob Res 2001;3:383-90.
56. Berlin I, Antenelli RM. Monoamine oxidase and tobacco smoking. Int J Neuropsychopharmacol 2001;4:33-42.
57. Corrigal WA, Coen KM. Nicotine maintains robust self-administration in rats in a limited access schedulr. Psychopharmacology 1989;99:473-9.
58. Levin ED, Briggs SJ, Christopher WC, Rose JE. Persistence of chronic nicotine induced cognitive facilitation. Behav Neural Biol 1992;58:152-6.
59. Levin ED. Nicotine systems and cognitive functions. Psychopharmacology 1992;108:417-31.
60. Hildebrand BE, Nomokos GG, Bondjers C, Nisell M, Svensson TH. Behavioural manifestations of nicotine abstinence in rat: Peripheral versus central mechanisms. Psychopharmacology 1997;129:348-56.
61. Donny EC, Caggiula AR, Rowett PP, Ghurib MA, Maldovan V, Booth S. Differential effects of response-contingent and response independent nicotine in rats. Eur J Pharmacol 2000;402:231-40.
62. Wonnacott S. The paradox of nicotine acvetylcholine receptor upregulation by nicotine. Trends Pharmacol Sci 1990;11:216-9.
63. Robinson SF, Marks MJ, Collins AC. Inbred mouse strains vary in oral self-selection of nicotine. Psychopharmacology 1996;124:332-9.
64. Singer M, Wallace M, Hall R. Effect of dopaminergic nucleus accumbens lesions on acquisition of schedule induced self injection of nicotine in the rat. Pharmacol Biochem Behav 1982;17:579-81.
65. Rose JE, Behm FM, Levin ED. Role of nicotine dose and sensory cues in the regulation of smoke intake. Pharmacol Biochem Behav 1993; 44:891-900.
66. Fiore MC, Bailey WC, Cohen SJ. Treating tobacco use and dependence: Clinical practice guidelines. Rockville MD: US Department of Health and Human Services. Ublic Health Service; 2000.
67. Henningfield JE. Nicotine medication for smoking-cessation. N Engl J Med 1995;333:1196-203.
68. Giovino GA, Henningfied JE, Tomar SL, Escobedo LG, Slade J. Epidemiology to tobacco use and dependence. Epidemiol Rev 1995;17:48-65.
69. Gourlay SG, Benowitz NL. It clonidine an effective smoking cessation therapy? Drugs 1995;50:197-207.
70. Coe JW, Brroks PR, Vetelino MG. Varenicline: An alfa4-beta2 nicotine receptor partial agonist for smoking cessation. J Med Chem 2005;48:3473-7.
71. Paddock C. Vaccine to treat nicotine addiction steps closer to market as companies agree option deal. Rockville, Maryland, US: Medical News Today; 2009.